Femasys (FEMY) AI Stock Analysis

• Market Cap: $31.22M
• Dividend Yield: N/A
• Average Volume (3M): 492.55K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.46
• Revenue Growth: 51.97%
• EPS Growth: 9.94%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 74
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.84
• Shares Outstanding: 27,149,971
• 10 Day Avg. Volume: 356,676
• 30 Day Avg. Volume: 492,548
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 29.06
• Price to Cash Flow (P/CF): -1.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $9.00
• Price Target Upside: 703.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Femasys faces significant financial challenges with ongoing losses and cash flow problems. While technical indicators show some bearish sentiment, the valuation metrics highlight the company's struggle to achieve profitability, making it a risky investment. Improvement in financial health is necessary for a better outlook.

Positive Factors

Partnerships

Femasys announced a partnership with CNY Fertility to introduce its artificial insemination treatment, FemaSeed, at 11 CNY locations, further expanding access across the US.

Regulatory Approvals

FemaSeed obtained FDA 510(k) clearance and is approved globally, having obtained CE Mark (EU), MHRA (UK), and AMAR (Israel) approvals.

Negative Factors

Clinical Trial Concerns

Several alterations were made to the FemBloc procedure with several unintended pregnancies occurring, which are being evaluated in the ongoing pivotal study.

Financial Performance

4Q24 and FY24 revenues were lower than estimated, though momentum into 2025 is positive.

Femasys Business Overview & Revenue Model

Company Description

Femasys Inc. (FEMY) is a biomedical company focused on advancing women's healthcare by developing innovative, non-surgical medical solutions. The company operates within the healthcare sector, specifically targeting the areas of reproductive health and infertility. Its core products include the FemVue Saline-Air device for fallopian tube assessment and FemBloc, a permanent contraceptive solution currently in development.

How the Company Makes Money

Femasys generates revenue primarily through the sale and distribution of its medical devices and technologies aimed at improving women's reproductive health. The company earns income from its flagship product, FemVue, which is utilized in clinical settings for diagnostic purposes. Additionally, as Femasys advances its product pipeline, regulatory approvals and successful commercialization of products like FemBloc are expected to become significant future revenue streams. Partnerships with healthcare providers and clinics further bolster its market presence and sales potential.

Femasys Financial Statement Overview

Summary

Femasys is facing financial headwinds with persistent losses and cash flow issues. While there's some revenue growth, it is overshadowed by operational inefficiencies and financial instability. Strengthening financial health and achieving profitability are crucial for future sustainability.

Income Statement

Femasys has shown a slight increase in revenue over the years, but the company remains unprofitable with consistent negative EBIT and EBITDA margins. The net profit margin remains negative, and the revenue growth rate is volatile, suggesting challenges in achieving stable growth.

Balance Sheet

The balance sheet reflects financial instability with a negative equity position in earlier years, improving to positive but weak equity levels recently. The debt-to-equity ratio indicates high leverage, which could pose risks if not managed carefully. The company needs to strengthen its equity base for financial stability.

Cash Flow

Femasys consistently experiences negative operating and free cash flows, indicating operational challenges and a reliance on external financing. The cash flow to net income ratios are unfavorable, emphasizing the company's struggle to generate cash through operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.26M	1.63M	1.07M	1.21M	1.18M	1.04M
	Gross Profit
363.82K	1.63M	691.90K	764.28K	809.30K	731.38K
	EBIT
-17.51M	-17.79M	-14.51M	-11.60M	-8.34M	-6.93M
	EBITDA
-15.89M	-20.11M	-13.17M	-10.49M	-6.55M	-5.80M
	Net Income Common Stockholders
-18.10M	-18.82M	-14.25M	-11.39M	-7.54M	-6.91M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.41M	0.00	21.72M	12.96M	24.78M	3.32M
	Total Assets
0.00	0.00	27.76M	16.90M	28.58M	7.61M
	Total Debt
0.00	7.44M	6.70M	543.72K	990.21K	2.06M
	Net Debt
7.41M	7.44M	-15.02M	-12.42M	-23.79M	-1.27M
	Total Liabilities
0.00	1.56M	9.40M	1.65M	2.24M	59.42M
	Stockholders Equity
9.97M	2.30M	18.35M	15.24M	26.33M	-51.82M
Cash Flow		Free Cash Flow
-18.19M	-20.21M	-11.42M	-11.14M	-8.24M	-4.96M
	Operating Cash Flow
-17.41M	-19.44M	-11.28M	-10.73M	-7.93M	-4.93M
	Investing Cash Flow
-782.05K	-847.76K	-143.92K	-407.48K	-306.87K	968.32K
	Financing Cash Flow
17.11M	2.03M	20.18M	-681.64K	29.70M	871.65K

Femasys Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Negative. The current price of 1.12 is below the 20-day moving average (MA) of 1.39, below the 50-day MA of 1.41, and below the 200-day MA of 1.19, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 34.82 is Neutral, neither overbought nor oversold. The STOCH value of 9.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FEMY.

Femasys Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	67 Neutral	$1.06B	25.17	25.01%	―	8.52%	-32.91%
VERU	52 Neutral	$83.42M	―	-80.11%	―	-7.43%	69.03%
Sector *	48 Neutral	$6.36B	1.24	-44.94%	2.70%	18.33%	1.47%
CTSO	44 Neutral	$58.75M	―	-120.52%	―	-2.08%	40.07%
EVFM	44 Neutral	$1.02M	―	12.00%	―	6.28%	-102.41%
FEMY	39 Underperform	$31.22M	―	-182.18%	―	51.97%	9.94%
HSDT	39 Underperform	$1.99M	―	-688.88%	―	-19.25%	59.74%

Femasys Corporate Events

Femasys Advances in Women’s Health Innovation

Femasys Inc., a pioneering company in women’s reproductive health, is gaining attention with its innovative approach to fertility, contraception, and cancer diagnostics. With a strong focus on providing accessible, in-office solutions, Femasys aims to tap into significant global market opportunities. The company boasts an impressive portfolio, including FDA-cleared products and a robust pipeline. As a woman-led firm, Femasys is well-positioned with a strategic commercial-readiness plan and holds over 180 patents worldwide, drawing interest from investors and stakeholders in the financial markets.